跳至主要内容
临床试验/NCT04069845
NCT04069845Unknown不适用

A Registry Study on the Risk Factors of Interstitial Pneumonia in Lymphoma Patients Treated With Liposomal Doxorubicin

Ruijin Hospital1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2019年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
2,000
试验地点
1
主要终点
the incidence of interstitial pneumonia

研究概览

简要总结

This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • histologically confirmed lymphoma
  • 18-80 years
  • ECOG<= 2
  • newly diagnosed lymphoma
  • liposomal doxorubicin is planned in the treatment
  • normal lung function
  • no history or malignancy
  • informed consented

排除标准

  • history of malignancy, now in the treatment
  • serious infection
  • other uncontrollable conditions judged by the investigator

研究组 & 干预措施

liposomal doxorubicin treatment

intravenous liposomal doxorubicin

干预措施: liposomal doxorubicin (Drug)

结局指标

主要结局

the incidence of interstitial pneumonia

时间窗: up to one month after completion of study treatment

interstitial pneumonia is defined as positive CT scan with or without positive respiratory symptoms

次要结局

  • adverse events(up to 30 days after completion of study treatment)
  • overall response rate(21 days after completion of study treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhao Weili

professor

Ruijin Hospital

研究点 (1)

Loading locations...

相似试验